Product Information

LAMIVUDINE 150 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $0.4887 per EA under NDC 64380071003. Its NADAC has been published 394 times since Sep 12, 2018.

FDA first approved this application on Apr 19, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

LAMIVUDINE 150 MG TABLET

Lamivudine
$0.4887per EA

Strength

150 mg/1

NDC

64380071003

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

LAMIVUDINE

Approval Type

Generic (ANDA)

FDA Application

ANDA090457

FDA Approved

4/19/2018

TE Code

AB

On Market Since

10/19/2018

Price Statistics

The NADAC for LAMIVUDINE 150 MG TABLET has been published 394 times since Sep 12, 2018, and over the history we have for it it has declined 53.6%. The table below summarizes its recorded NADAC range and movement.

Current price$0.4887 per EA
All-time high$1.2884 (Jan 16, 2019)
All-time low$0.4126 (Oct 22, 2025)
52-week high$0.4887
52-week low$0.4126
Median price$0.8475
Average price$0.8019
Largest weekly change+54.1% (May 22, 2019)
Weeks tracked394
Tracking sinceSep 12, 2018

Price History

1W

+4.0%

1M

+4.0%

3M

+8.9%

6M

+14.9%

1Y

+1.9%

3Y

-42.3%

5Y

-52.0%

All

-53.6%

Generic Alternatives

The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of LAMIVUDINE 150 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE 150 MG TABLET, manufactured by Strides Pharma Inc., is $0.4887 per EA (NDC 64380071003), effective Aug 19, 2026.

How has the price of LAMIVUDINE 150 MG TABLET changed over time?

Over the history we have for it, the NADAC for LAMIVUDINE 150 MG TABLET has declined 53.6%. It has been tracked across 394 weekly CMS publications since Sep 12, 2018.

What are the highest and lowest recorded NADAC prices for LAMIVUDINE 150 MG TABLET?

Since Sep 12, 2018, the NADAC for LAMIVUDINE 150 MG TABLET has ranged from a low of $0.4126 (Oct 22, 2025) to a high of $1.2884 (Jan 16, 2019), with a median of $0.8475 per EA.

Are there cheaper alternatives to LAMIVUDINE 150 MG TABLET?

Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LAMIVUDINE 150 MG TABLET, is $0.4797 per EA — about 2% below LAMIVUDINE 150 MG TABLET.

Who manufactures LAMIVUDINE 150 MG TABLET?

LAMIVUDINE 150 MG TABLET (NDC 64380071003) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.